Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

The DREAM trial.

Nissen SE.

Lancet. 2006 Dec 9;368(9552):2049; author reply 2050-1. No abstract available.

PMID:
17161720
2.

Diabetes prevention: still no effective drugs.

[No authors listed]

Prescrire Int. 2007 Dec;16(92):258.

PMID:
18095391
3.

[Glitazone - mailing no 4. In response to DMW 49/2007].

Strohmeyer T, Seidel D.

Dtsch Med Wochenschr. 2008 Feb;133(6):262; author reply 262-3. doi: 10.1055/s-2008-1017511. German. No abstract available.

PMID:
18236358
4.

[Glitazone - mailing no 1. In response to DMW 49/2007].

Traut V.

Dtsch Med Wochenschr. 2008 Feb;133(6):261; author reply 262-3. doi: 10.1055/s-2008-1017508. German. No abstract available.

PMID:
18236356
5.

[Glitazone - mailing no 3. In response to DMW 49/2007].

Gundel UF.

Dtsch Med Wochenschr. 2008 Feb;133(6):261-2; author reply 262-3. doi: 10.1055/s-2008-1017510. German. No abstract available.

PMID:
18236354
6.

Rosiglitazone and cardiovascular risk.

Brett AS.

N Engl J Med. 2007 Aug 30;357(9):939; author reply 939-40. No abstract available.

PMID:
17806134
7.

[Glitazone - mailing no 2. In response to DMW 49/2007].

Kerner W.

Dtsch Med Wochenschr. 2008 Feb;133(6):261; author reply 262-3. doi: 10.1055/s-2008-1017509. German. No abstract available.

PMID:
18236355
8.

The Avandia debate: an unhappy conclusion.

Bloomgarden Z, Handelsman Y.

J Diabetes. 2010 Dec;2(4):221-2. doi: 10.1111/j.1753-0407.2010.00096.x. No abstract available.

9.

[Determining the current position regarding the value of pioglitazone for the therapy of diabetes].

Eckert S, Erdmann E, Lundershausen R, Forst T, Scherbaum WA, Schnell O, Standl E, Schumm-Draeger PM, Tschöpe D, Walter H, Weber M.

Dtsch Med Wochenschr. 2007 Dec;132(49):2650-3. German. No abstract available.

PMID:
18050033
10.

Future directions for insulin sensitizers in disease prevention.

Colca JR.

Curr Opin Investig Drugs. 2007 Sep;8(9):707-10. Review. No abstract available.

PMID:
17729181
11.

Rosiglitazone and cardiotoxicity--weighing the evidence.

Nathan DM.

N Engl J Med. 2007 Jul 5;357(1):64-6. Epub 2007 Jun 5. No abstract available.

12.

[Rosiglitazone--statistics for benefits and problems].

Hjelmesaeth J, Røislien J.

Tidsskr Nor Laegeforen. 2007 Oct 18;127(20):2702-3. Norwegian. No abstract available.

13.

Rosiglitazone and cardiovascular risk: weighing recent evidence.

Stafylas PC, Sarafidis PA, Lasaridis AN.

J Cardiometab Syndr. 2007 Fall;2(4):295-6. Review. No abstract available.

14.

Pioglitazone for diabetes prevention.

Goldstein MR, Mascitelli L.

N Engl J Med. 2011 Jul 14;365(2):183; author reply 183-4. doi: 10.1056/NEJMc1104572#SA2. No abstract available.

PMID:
21751925
15.

[Glitazones critically evaluated].

Schernthaner G.

Dtsch Med Wochenschr. 2007 Dec;132(49):2619. German. No abstract available.

PMID:
18050024
16.

[Too positive comment on glitazones].

Lindberg M.

Ugeskr Laeger. 2007 Feb 19;169(8):733; author reply 733. Danish. No abstract available.

PMID:
17338040
17.

Glucose lowering and diabetes prevention: are they the same?

Tuomilehto J, Wareham N.

Lancet. 2006 Oct 7;368(9543):1218-9. No abstract available.

PMID:
17027710
18.

Do thiazolidinediones increase the risk of cardiovascular events?

Ribowsky J, Covino J.

JAAPA. 2008 Aug;21(8):53-4. No abstract available.

PMID:
18795550
19.

Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes?

Vaccaro O, Riccardi G.

Nutr Metab Cardiovasc Dis. 2008 Feb;18(2):85-7. doi: 10.1016/j.numecd.2008.01.003. Epub 2008 Feb 15. No abstract available.

PMID:
18280715
20.

Rosiglitazone--continued uncertainty about safety.

Drazen JM, Morrissey S, Curfman GD.

N Engl J Med. 2007 Jul 5;357(1):63-4. Epub 2007 Jun 5. No abstract available.

Supplemental Content

Support Center